Search - tctmd.com

Displaying 1 - 7 of 7

Sort: Relevancy | Date

Presentation TCT 2018

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

Presenter: E. Magnus Ohman, Stuart J. Pocock, David J. Maron

September 23, 2018

Presentation TCT 2018

How the Best-CLI Trial Will Change Clinical Practice

Presenter: Ehrin J. Armstrong, Sahil A. Parikh, Matthew T. Menard

September 22, 2018

Presentation TCT 2018

PCI for Ischemia Part II: Why the ISCHEMIA Trial Might be Positive..or Negative!

Presenter: David J. Cohen, Sunil V. Rao, Ajay J. Kirtane

September 22, 2018

Presentation TCT 2018

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

Presenter: David J. Cohen, Sunil V. Rao, Bernard J. Gersh

September 22, 2018

Presentation TCT 2018

TCT-115: Long-Term Follow-up of the PADI Trial: Percutaneous Transluminal Angioplasty Versus Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia

Presenter: J. Michael Bacharach, Tony Das, Thijs Wakkie

September 21, 2018

Presentation TCT 2018

Percutaneous Deep Vein aRterialization for the Treatment of Late Stage Critical LiMb ISchEmia, The PROMISE Trial: Early Feasibility Interim Results (LimFlow)

Presenter: George L Adams, Tony Das, Steve Henao

September 21, 2018

Presentation ACC 2018

A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial)

Presenter: Mehdi H. Shishehbor

March 12, 2018

Advertisement

ISCHEMIA Trial in the Spotlight: Why All the Fuss Over the Change in the Primary Endpoint?

How the Best-CLI Trial Will Change Clinical Practice

PCI for Ischemia Part II: Why the ISCHEMIA Trial Might be Positive..or Negative!

PCI for Ischemia Part I: Critical Analysis of the FAME Trials and ORBITA

TCT-115: Long-Term Follow-up of the PADI Trial: Percutaneous Transluminal Angioplasty Versus Drug-Eluting Stents for Infrapopliteal Lesions in Critical Limb Ischemia

Percutaneous Deep Vein aRterialization for the Treatment of Late Stage Critical LiMb ISchEmia, The PROMISE Trial: Early Feasibility Interim Results (LimFlow)

A Phase II Randomized Double-Blind, Placebo Controlled Study in Patients with Critical Limb Ischemia to Evaluate the Safety and Efficacy of hSDF-1 plasmid (JVS-100) Post Open or Endovascular Revascularization (STOP-PAD Trial)

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content